KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Liabilities and Shareholders Equity (2016 - 2025)

CRISPR Therapeutics AG's Liabilities and Shareholders Equity history spans 11 years, with the latest figure at $2.3 billion for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 1.04% year-over-year to $2.3 billion; the TTM value through Dec 2025 reached $8.7 billion, down 6.15%, while the annual FY2025 figure was $2.3 billion, 1.04% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $2.3 billion at CRISPR Therapeutics AG, up from $2.2 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $2.9 billion in Q2 2021 and bottomed at $2.0 billion in Q1 2021.
  • The 5-year median for Liabilities and Shareholders Equity is $2.3 billion (2024), against an average of $2.3 billion.
  • The largest annual shift saw Liabilities and Shareholders Equity skyrocketed 177.06% in 2021 before it decreased 18.49% in 2022.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $2.8 billion in 2021, then dropped by 18.49% to $2.2 billion in 2022, then decreased by 0.6% to $2.2 billion in 2023, then rose by 0.56% to $2.2 billion in 2024, then increased by 1.04% to $2.3 billion in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Liabilities and Shareholders Equity are $2.3 billion (Q4 2025), $2.2 billion (Q3 2025), and $2.0 billion (Q2 2025).